yervoy 200 mg/40 ml concentrato per soluzione per infusione
bristol-myers squibb sa - ipilimumabum - concentrato per soluzione per infusione - ipilimumabum 200 mg, trometamoli hydrochloridum, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, natrii hydroxidum aut acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 40 ml corresp. natrium 92 mg. - melanoma, carcinoma a cellule renali, kolorektales carcinoma - biotechnologika
daklinza 30 mg filmtabletten
bristol-myers squibb sa - daclatasvirum - filmtabletten - tablet: daclatasvirum 30 mg ut daclatasviri dihydrochloridum, colore.: e 132, excipiens pro compresso obducto. - chronische epatite c - synthetika
daklinza 60 mg filmtabletten
bristol-myers squibb sa - daclatasvirum - filmtabletten - daclatasvirum 60 mg ut daclatasviri dihydrochloridum, colore.: e 132, excipiens pro compresso obducto. - chronische epatite c - synthetika
opdivo 40 mg/4 ml concentrato per soluzione per infusione
bristol-myers squibb sa - nivolumabum - concentrato per soluzione per infusione - nivolumabum 40 mg, natrii citras dihydricus, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 10 mg. - onkologikum - biotechnologika
opdivo 100 mg/10 ml concentrato per soluzione per infusione
bristol-myers squibb sa - nivolumabum - concentrato per soluzione per infusione - nivolumabum 100 mg, natrii citras dihydricus, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 25 mg. - onkologikum - biotechnologika
empliciti 300 mg polvere per soluzione per infusione
bristol-myers squibb sa - elotuzumabum - polvere per soluzione per infusione - elotuzumabum 300 mg, natrii citras dihydricus corrisp. sodio 3.9 mg, acido citricum monohydricum, zucchero, polysorbatum 80 per il vetro. - multipli myelom - biotechnologika
empliciti 400 mg polvere per soluzione per infusione
bristol-myers squibb sa - elotuzumabum - polvere per soluzione per infusione - elotuzumabum 400 mg, natrii citras dihydricus corrisp. sodio 5.3 mg, acido citricum monohydricum, zucchero, polysorbatum 80 per il vetro. - multipli myelom - biotechnologika
opdivo 240 mg/24 ml concentrato per soluzione per infusione
bristol-myers squibb sa - nivolumabum - concentrato per soluzione per infusione - nivolumabum 240 mg, natrii citras dihydricus, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 24 ml corresp. natrium 60 mg. - onkologikum - biotechnologika
zeposia
bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosoppressori - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
reblozyl
bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - altre antianemico preparazioni - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.